Siludi Pharmaceutical Co., Ltd. (01244) fell by more than 15%, hitting a record low of HK$2.31. Currently, the market capitalization is only HK$0.599 billion, which has evaporated over 33 billion from its highest point.
The Zhitong Finance App learned that Siludi Pharmaceutical Co., Ltd. (01244) fell by more than 15%, hitting a new low of HK$2.31. The current market value is only HK$0.599 billion, and has evaporated over 33 billion from its highest point. As of press release, it fell 15.27% to HK$2.33, with a turnover of HK$1.2322 million.
According to the news, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently issued announcements to make adjustments to the Hong Kong Stock Exchange's list of securities. Among them, Siludi Pharmaceutical Co., Ltd. was transferred out of Hong Kong Stock Connect, effective September 10. In the first half of this year, Siludi Pharmaceutical Co., Ltd. achieved revenue of 0.206 billion yuan (RMB, same below), a year-on-year decrease of 41.4%; loss was 0.1035 billion yuan, a decrease of 42% year-on-year. All of the company's revenue during the period came from sales of the commercialized product Envida (envolimab, subcutaneous PD-L1 inhibitor) by distributors directly cooperating with. The decline in revenue is a result of intense competition in the PD-1/L1 market in 2024.
